Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today that the Phase III, double-blind, placebo-controlled clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback